In summary, identified signaling was unique to volasertib mediated anti-tumor response in glioblastoma and provide additional support for the PLK1 inhibition as an adjunct to SOC in glioma and the search for biomarkers that predict its efficacy. The gene discussed is PLK1; the disease is central nervous system cancer.